Pirooz Zareie

Pirooz Zareie

Auto-generated profile, based on publicly available information

Pirooz Zareie

Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
AWAmy L. Winship
Amy L. Winship
LALauren R. Alesi
Lauren R. Alesi
SSSneha Sant
Sneha Sant
JSJessica M. Stringer
Jessica M. Stringer
ACAldana Cantavenera
Aldana Cantavenera
KHKarla Hutt
Karla Hutt

4 June 2021 in Science
Verified
Journal Article
Closed access
PDF file
PZPirooz Zareie
Pirooz Zareie
CSChristopher Szeto
Christopher Szeto
CFCarine Farenc
Carine Farenc
SGSachith D. Gunasinghe
Sachith D. Gunasinghe
EKElizabeth Motunrayo Kolawole
Elizabeth Motunrayo Kolawole
NGNicole La Gruta
Nicole La Gruta
Making sense of TCR–pMHC topology: Most T cells use a T cell receptor (TCR) that recognizes major histocompatibility complex molecules bound to peptides (pMHCs) derived from both self- and foreign antigens. Although there is great variability in the interface because of the diversity of both partners, this interaction displays a canonical docking topology for reasons that remain contested. Zareie et al. tested an assortment of both canonical and reversed-polarity TCRs that were all specific for the same cognate pMHC-I bearing a peptide derived from influenza A virus (IAV) (see the Perspective by Horkova and Stepanek). The authors determined that docking topology was the primary driver of in vivo T cell activation and recruitment when mice were infected with IAV. The canonical topology was required for the formation of a functional signaling complex, suggesting that T cell signaling constraints dictate how TCR and pMHC meet. Science , abe9124, this issue p. eabe9124 ; see also abj2937, p. 1038

1 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DODavid O'Sullivan
David O'Sullivan
LGLaura Green
Laura Green
SSSarrabeth Stone
Sarrabeth Stone
PZPirooz Zareie
Pirooz Zareie
MKMarie Kharkrang
Marie Kharkrang
AFAnne Camille La Flamme
Anne Camille La Flamme
Recent studies have demonstrated that atypical antipsychotic agents, which are known to antagonize dopamine D2 and serotonin 5-HT2a receptors, have immunomodulatory properties. Given the potential of these drugs to modulate the immune system both peripherally and within the central nervous system, we investigated the ability of the atypical anti-psychotic agent, risperidone, to modify disease in the animal model of multiple sclerosis (MS)4, experimental autoimune encephalomyelitis (EAE). We found that chronic oral administration of risperidone dose-dependently reduced the severity of disease and decreased both the size and number of spinal cord lesions. Furthermore, risperidone treatment substantially reduced antigen-specific interleukin (IL)-17a, IL-2, and IL-4 but not interferon (IFN)-γ production by splenocytes at peak disease and using an in vitro model, we show that treatment of macrophages with risperidone alters their ability to bias naïve T cells. Another atypical antipsychotic agent, clozapine, showed a similar ability to modify macrophages in vitro and to reduce disease in the EAE model but this effect was not due to antagonism of the type 1 or type 2 dopamine receptors alone. Finally, we found that while risperidone treatment had little effect on the in vivo activation of splenic macrophages during EAE, it significantly reduced the activation of microglia and macrophages in the central nervous system. Together these studies indicate that atypical antipsychotic agents like risperidone are effective immunomodulatory agents with the potential to treat immune-mediated diseases such as MS.

2 April 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
JLJia Jia Lim
Jia Jia Lim
CJClaerwen M. Jones
Claerwen M. Jones
TLTiing Jen Loh
Tiing Jen Loh
YTYi Tian Ting
Yi Tian Ting
PZPirooz Zareie
Pirooz Zareie
JRJamie Rossjohn
Jamie Rossjohn
Individuals expressing HLA-DR4 bearing the shared susceptibility epitope (SE) have an increased risk of developing rheumatoid arthritis (RA). Posttranslational modification of self-proteins via citrullination leads to the formation of neoantigens that can be presented by HLA-DR4 SE allomorphs. However, in T cell–mediated autoimmunity, the interplay between the HLA molecule, posttranslationally modified epitope(s), and the responding T cell repertoire remains unclear. In HLA-DR4 transgenic mice, we show that immunization with a Fibβ-74cit69-81 peptide led to a population of HLA-DR4Fibβ-74cit69-81 tetramer+ T cells that exhibited biased T cell receptor (TCR) β chain usage, which was attributable to selective clonal expansion from the preimmune repertoire. Crystal structures of pre- and postimmune TCRs showed that the SE of HLA-DR4 represented a main TCR contact zone. Immunization with a double citrullinated epitope (Fibβ-72,74cit69-81) altered the responding HLA-DR4 tetramer+ T cell repertoire, which was due to the P2-citrulline residue interacting with the TCR itself. We show that the SE of HLA-DR4 has dual functionality, namely, presentation and a direct TCR recognition determinant. Analogous biased TCR β chain usage toward the Fibβ-74cit69-81 peptide was observed in healthy HLA-DR4+ individuals and patients with HLA-DR4+ RA, thereby suggesting a link to human RA.

23 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSChristopher Szeto
Christopher Szeto
PZPirooz Zareie
Pirooz Zareie
RWRushika C. Wirasinha
Rushika C. Wirasinha
JZJustin B. Zhang
Justin B. Zhang
ANAndrea T. Nguyen
Andrea T. Nguyen
SDStephen R. Daley
Stephen R. Daley
Interactions between a T cell receptor (TCR) and a peptide-major histocompatibility complex (pMHC) ligand are typically mediated by noncovalent bonds. By studying T cells expressing natural or engineered TCRs, here we describe covalent TCR-pMHC interactions that involve a cysteine-cysteine disulfide bond between the TCR and the peptide. By introducing cysteines into a known TCR-pMHC combination, we demonstrate that disulfide bond formation does not require structural rearrangement of the TCR or the peptide. We further show these disulfide bonds still form even when the initial affinity of the TCR-pMHC interaction is low. Accordingly, TCR-peptide disulfide bonds facilitate T cell activation by pMHC ligands with a wide spectrum of affinities for the TCR. Physiologically, this mechanism induces strong Zap70-dependent TCR signaling, which triggers T cell deletion or agonist selection in the thymus cortex. Covalent TCR-pMHC interactions may thus underlie a physiological T cell activation mechanism that has applications in basic immunology and potentially in immunotherapy.

17 March 2017 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
LGLaura K Green
Laura K Green
PZPirooz Zareie
Pirooz Zareie
NTNikki Templeton
Nikki Templeton
RKRobert A Keyzers
Robert A Keyzers
BCBronwen Connor
Bronwen Connor
AFAnne Camille La Flamme
Anne Camille La Flamme
Background: Atypical antipsychotic agents (AAP) alleviate the symptoms of severe mental health disorders, such as schizophrenia, by antagonizing dopamine and serotonin receptors. Recently, AAP have also been shown to exhibit immunomodulatory properties in the central nervous system (CNS). Objective: Building on research which demonstrated the ability of the AAP risperidone and clozapine to modify the disease course of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), we aimed to more fully investigate the potential of clozapine as a possible treatment for MS. Results: We report that orally administered clozapine significantly reduced the disease severity of EAE in a dose-dependent manner and was effective when administered prophylactically and therapeutically. In comparison to risperidone, quetiapine, and olanzapine, clozapine was the best at reducing disease severity. While clozapine-treated mice had only modest changes to peripheral leukocytes and cytokine responses, these animals had significantly fewer CNS-infiltrating CD4 T cells and myeloid cells. Furthermore, the CNS myeloid cells displayed a less activated phenotype in mice treated with clozapine. Finally, we found that co-administration of clozapine with glatiramer acetate enhanced disease protection compared to either treatment alone. Conclusion: These studies indicate that clozapine is an effective immunomodulatory agent with the potential to treat immune-mediated diseases such as MS.